Advertisement

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

John C. Byrd, Peter Hillmen, Susan O’Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James and Jennifer R. Brown

Article Information

Citation 
vol. 133 no. 19 2031-2042
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted August 21, 2018
  • Accepted January 26, 2019
  • Published online May 9, 2019.

Article Versions


Contributors 
  • John C. Byrd, 1The Ohio State University Comprehensive Cancer Center, Columbus, OH;
  • Peter Hillmen, 2The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom;
  • Susan O’Brien, 3UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, CA;
  • Jacqueline C. Barrientos, 4Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY;
  • Nishitha M. Reddy, 5Vanderbilt-Ingram Cancer Center, Nashville, TN;
  • Steven Coutre, 6Stanford University School of Medicine, Stanford, CA;
  • Constantine S. Tam, 7Department of Haematology, Peter MacCallum Cancer Centre and St. Vincent’s Hospital, Melbourne, VIC, Australia;
  • Stephen P. Mulligan, 8Royal North Shore Hospital, Sydney, NSW, Australia;
  • Ulrich Jaeger, 9Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria;
  • Paul M. Barr, 10University of Rochester Medical Center, Rochester, NY;
  • Richard R. Furman, 11Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY;
  • Thomas J. Kipps, 12UCSD Moores Cancer Center, San Diego, CA;
  • Patrick Thornton, 13Beaumont Hospital, Dublin, Ireland;
  • Carol Moreno, 14Hospital de la Santa Creu Sant Pau, Barcelona, Spain;
  • Marco Montillo, 15Niguarda Ca’ Granda Hospital, Milan, Italy;
  • John M. Pagel, 16Swedish Cancer Institute Hematologic Malignancies Program, Seattle, WA;
  • Jan A. Burger, 17University of Texas MD Anderson Cancer Center, Houston, TX;
  • Jennifer A. Woyach, 1The Ohio State University Comprehensive Cancer Center, Columbus, OH;
  • Sandra Dai, 18Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and
  • Remus Vezan, 18Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and
  • Danelle F. James, 18Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and
  • Jennifer R. Brown, 19CLL Center, Dana-Farber Cancer Institute, Boston, MA

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output